The 20 Best Chronic B-Cell Leukemia (CBCL) Doctors Near Me in Towson, MD

Dr. Nina Wagner-Johnston is Professor of Oncology at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include non-Hodgkin lymphoma, Hodgkin lymphoma, and HIV-related lymphomas. Dr. Wagner-Johnston serves as the Director for the Lymphoma Drug Development Program at the Johns Hopkins University. Dr. Wagner-Johnston received her baccalaureate degree in nursing from Georgetown University in Washington, DC. She earned her MD and completed her residency training at the University of Chicago, Chicago Illinois. She performed a fellowship in Medical Oncology at Johns Hopkins University, Baltimore, Maryland. Dr. Wagner-Johnston joined the Johns Hopkins faculty in 2015. Prior to joining Johns Hopkins, Dr. Wagner-Johnston was an Assistant Professor at Washington University, St. Louis, Missouri. Her research interests include clinical trial and biomarker development for patients with lymphoma. She is additionally involved in palliative/supportive care research and has a particular interest in chemotherapy-induced peripheral neuropathy. Dr. Wagner-Johnston serves as a member on the NCCN Cancer Related Fatigue Guidelines Panel and the ASCO Neuropathy Guidelines Panel. She has served as a journal reviewer for Annals of Oncology, Leukemia and Lymphoma, Blood, and the Journal of Nuclear Medicine. She is a previous recipient of a Young Investigator Award at the Supportive Oncology Conference as well as a Mentoring Program Award through the American Academy of Hospice and Palliative Medicine. She has served on the National Cancer Institute (NCI) Lymphoma Steering Committee Clinical Trials Design Committee and the NCI Symptom Management and Health Related Quality of Life Steering Committee. She is a member of the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), the AIDS Malignancies Consortium (AMC), and the Eastern Cancer Oncology Group (ECOG) Lymphoma Committee. Dr. Wagner is rated as a Distinguished provider by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). Her top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration.

William Houck is an Oncologist in Baltimore, Maryland. Dr. Houck is rated as a Distinguished provider by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). His top areas of expertise are Paget Disease of the Breast, Lung Cancer, Chronic Lymphocytic Leukemia (CLL), and Chronic B-Cell Leukemia (CBCL).

Dr. Lode J. Swinnen is a cancer specialist in Baltimore caring for patients with lymphoma. Dr. Swinnen received his M.B.Ch.B. degree from the University of Cape Town Medical School. He completed his residency at Presence Saint Joseph Hospital and performed a fellowship in hematology-oncology at Loyola University Stritch School of Medicine. Dr. Swinnen joined the Johns Hopkins faculty in 2002. His research interests include lymphomas and immunodeficiency-associated malignancies. Dr. Swinnen is a member of the Eastern Cooperative Oncology Group and the National Comprehensive Cancer Network. Dr. Swinnen is rated as a Distinguished provider by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). His top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma, Small Lymphocytic Lymphoma (SLL), and Bone Marrow Transplant.

Syed Nasir is an Oncologist in Towson, Maryland. Dr. Nasir is rated as an Advanced provider by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Lynch Syndrome, and Paget Disease of the Breast. Dr. Nasir is currently accepting new patients.

Maitri Kalra is a Hematologist Oncology specialist and an Oncologist in Lutherville, Maryland. Dr. Kalra has been practicing medicine for over 17 years and is rated as an Experienced provider by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, and Angiosarcoma.

Richard F. Ambinder, M.D., Ph.D., currently serves as the James B. Murphy Professor of Oncology and the Director of the Division of Hematologic Malignancies at the Johns Hopkins Kimmel Cancer Center. He is program co-leader of the Hematologic Malignancies and Bone Marrow Transplantation Program and leads the AIDS Malignancy Consortium (AMC) site at Johns Hopkins and the AMC Translational Sciences Working Group nationally. Dr. Ambinder graduated from Harvard College with a Bachelor’s degree in biochemistry, after which he received his medical degree from the Johns Hopkins University School of Medicine before completing his residency at the Johns Hopkins Hospital. He also earned his Ph.D. in pharmacology from the Johns Hopkins University, and completed his oncology fellowship at Johns Hopkins. Within the clinic, Dr. Ambinder is active in the treatment of lymphoma and Kaposi’s sarcoma. Dr. Ambinder’s research is focused on exploring opportunities to prevent or treat cancer with viral infections. Virus-associated tumors are among the most common malignancies in certain populations and regions. For instance, Burkitt's lymphoma (EBV) and Kaposi's sarcoma (KSHV) are common in equatorial Africa, nasopharyngeal carcinoma (EBV) is common in southern Chinese populations or those with southern Chinese origins, and immunoblastic lymphomas (EBV) are common in immunocompromised patients (organ transplant recipients, AIDS patients, etc). Thus, Dr. Ambinder’s new approaches to prevention, diagnosis, and treatment stand to have a direct impact on the lives of cancer patients around the globe. Additionally, the study of how viruses can impact these tumors is important in creating model systems for the development of new approaches to cancer care. Currently, many immunotherapies target unidentified antigens, making the measurement of relevant immune responses problematic at best. However, in EBV-associated tumors the antigens are well defined, thus allowing the Ambinder lab to define the epitope-specific cellular immune responses. As a result of this breakthrough, interventions designed to alter immune response —whether they be vaccine based interventions, adoptive immunotherapy interventions, or pharmacologic interventions — may all be assessed in terms of relevant surrogate markers. Much in the same way the treatment of Hodgkin's lymphoma with radiotherapy and chemotherapy paved the way for the modern approach to cancer treatment more broadly, the treatment of EBV-associated tumors (including Hodgkin's lymphoma) may pave the way to the more generalized use of these modalities to treat a myriad of cancer types. Dr. Ambinder is rated as an Advanced provider by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). His top areas of expertise are Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Tissue Biopsy, and Bone Marrow Aspiration.

Gang Chen is a Hematologist in Towson, Maryland. Dr. Chen is rated as an Experienced provider by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). His top areas of expertise are Colorectal Cancer, Myelodysplastic Syndrome (MDS), Familial Colorectal Cancer, and Paget Disease of the Breast.

Richard Schraeder is a Hematologist and an Oncologist in Towson, Maryland. Dr. Schraeder is rated as an Advanced provider by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Small Cell Lung Cancer (SCLC), and Retroperitoneal Liposarcoma. Dr. Schraeder is currently accepting new patients.

Robert Donegan is a Hematologist in Towson, Maryland. Dr. Donegan is rated as an Advanced provider by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Non-Hodgkin Lymphoma, and Angiosarcoma.

Mei Tang is a Hematologist in Towson, Maryland. Dr. Tang is rated as an Advanced provider by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). Her top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Myelodysplastic Syndrome (MDS), and Large-Cell Immunoblastic Lymphoma.

Paul Celano is an Oncologist in Baltimore, Maryland. Dr. Celano is rated as an Advanced provider by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). His top areas of expertise are Ovarian Cancer, Testicular Yolk Sac Tumor, Virilizing Ovarian Tumor, and Ovarian Carcinosarcoma.

Charles Padgett is a Hematologist in Baltimore, Maryland. Dr. Padgett is rated as an Advanced provider by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). His top areas of expertise are Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Large-Cell Lung Carcinoma.

Eric Seifter is an Oncologist in Lutherville, Maryland. Dr. Seifter is rated as an Advanced provider by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). His top areas of expertise are Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL), Richter Syndrome, and Chronic B-Cell Leukemia (CBCL).

Harry Kaplan is a primary care provider, practicing in Internal Medicine in Baltimore, Maryland. Dr. Kaplan is rated as an Advanced provider by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). His top areas of expertise are Chronic B-Cell Leukemia (CBCL), Anemia, Vitamin B12 Deficiency, Subacute Combined Degeneration, and Pacemaker Implantation.

Mayer Gorbaty is an Oncologist in Baltimore, Maryland. Dr. Gorbaty is rated as an Advanced provider by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). His top areas of expertise are Monoclonal Gammopathy of Undetermined Significance (MGUS), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin Lymphoma, and Multiple Myeloma.

Marvin Feldman is a Hematologist in Baltimore, Maryland. Dr. Feldman is rated as an Advanced provider by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). His top areas of expertise are Anal Cancer, Laryngeal Cancer, Familial Colorectal Cancer, and Angiosarcoma.

Dr. Civelek is a professor in the Johns Hopkins Medicine Department of Radiology and Radiological Science. He serves as the director of the Nuclear Medicine Residency Program. Dr. Civelek earned his medical degree at Istanbul University, Istanbul School of Medicine, and completed his residency at Hacettepe University Medical Center, Ankara. He received a scholarship from the International Atomic Energy Agency when he completed his nuclear medicine residency and fellowship at Johns Hopkins in the Division of Nuclear Medicine. After his period as a postdoctoral fellow, he joined Johns Hopkins Medicine as full-time faculty until 2003. In his early years at Johns Hopkins, Dr. Civelek assisted the clinical and research programs. He later served as director of nuclear cardiology and clinical director, the director of Nuclear Medicine Residency Program, as well as medical director of the Nuclear Medicine Technologist Program. Prior to his return to Johns Hopkins, Dr. Civelek was a professor and director of nuclear medicine and PET at the University of Louisville and a professor and director of nuclear medicine at the Saint Louis University Hospital. Dr. Civelek spent two years in the body MRI and MRI-PET section, Department of Radiology and Imaging Sciences, at National Institutes of Health Clinical Center before serving as the deputy chief in their nuclear medicine section. He is a fellow of the American College of Nuclear Medicine and The American College of Angiology, and is a fellow and founding member of the American Society of Nuclear Cardiology. Dr. Civelek has trained numerous American and international physicians in nuclear medicine, including nuclear cardiology and nuclear oncology. He has a worldwide reputation in nuclear medicine and lectures at medical centers in the U.S. and internationally on nuclear medicine, including nuclear cardiology and nuclear oncology/PET-CT and PET-MRI. Dr. Civelek is committed to the continued progress of nuclear medicine, cardiology and oncology and the development of new tumor-targeting radiopharmaceuticals for imaging and therapy. He supports high quality clinical trials and patient care and safety. To date, Dr. Civelek has published more than 210 peer-reviewed manuscripts and abstracts, and he has participated in and fostered many nuclear oncology research projects. He has served on the editorial boards of several journals. He is a reviewer for multiple scientific journals, including the Journal of Nuclear Medicine, American Journal of Radiology, and Journal of Urology. Dr. Civelek is rated as an Experienced provider by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). His top areas of expertise are Neuroendocrine Tumor, Prostate Cancer, Lung Cancer, and Familial Prostate Cancer.

Laura Wake, M.D., is a hematopathologist at the Johns Hopkins Hospital, and an Assistant Professor in the Department of Pathology at the Johns Hopkins University School of Medicine. Dr. Wake's pathology expertise extends to hematology and oncology. She specifically focuses on hematologic cancers and lymphoid malignancies. Dr. Wake earned her medical degree at the American University of the Caribbean School of Medicine. She completed an anatomic and clinical pathology residency at the University of Nebraska Medical Center and a hematopathology fellowship at the National Institutes of Health/National Cancer Institute. Dr. Wake is the Medical Director of the Johns Hopkins Hospital Flow Cytometry Laboratory and is the Program Director of the Hematopathology Fellowship at Johns Hopkins. Dr. Wake has contributed to numerous publications on hematopathology research. Dr. Wake is rated as an Experienced provider by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Acute Myeloblastic Leukemia with Maturation, Acute Myeloid Leukemia (AML), and Acute Myeloblastic Leukemia without Maturation.

I am a physician-scientist in the Division of Hematological Malignancies and stem cell transplantation at the Sidney Kimmel Comprehensive Cancer Center, where I specialize in the treatment of lymphomas. My primary research focuses on developing new biologic therapies for the treatment of T-cell lymphomas and T-cell leukemias. Dr. Paul is rated as an Experienced provider by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). His top areas of expertise are Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Burkitt Lymphoma, and Acute Myeloid Leukemia (AML).

Ravin Garg is a Hematologist Oncology specialist and an Oncologist in Baltimore, Maryland. Dr. Garg is rated as an Advanced provider by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). His top areas of expertise are Large-Cell Immunoblastic Lymphoma, Paget Disease of the Breast, Breast Cancer, and Thrombotic Thrombocytopenic Purpura.